| 2010 | Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes | BREAST CANCER RESEARCH AND TREATMENT |
| 2021 | Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib plus capecitabine (N plus C) vs lapatinib plus capecitabine (L plus C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens | BREAST CANCER RESEARCH AND TREATMENT |
| 2017 | Chemotherapy-induced irreversible alopecia in early breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib | BREAST CANCER RESEARCH AND TREATMENT |
| 2009 | Cost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC). | BREAST CANCER RESEARCH AND TREATMENT |
| 2005 | Cyclic induction of senescence with intermittent AZT treatment accelerates both apoptosis and telomere loss | BREAST CANCER RESEARCH AND TREATMENT |
| 2007 | Different criteria for HER2 positivity by IHC can be applied in post-chemotherapy specimens in determining HER2 as a prognosticator in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2017 | Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2005 | Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2011 | Identification of genes associated with chemosensitivity to SAHA/taxane combination treatment in taxane-resistant breast cancer cells | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Intermediate HER2 Expression Is Associated With Poor Prognosis in Estrogen Receptor-Positive Breast Cancer Patients Aged 55 Years and Older | BREAST CANCER RESEARCH AND TREATMENT |
| 2008 | Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 1997 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 1996 | P-glycoprotein: The intermediate end point of drug response to induction chemotherapy in locally advanced breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 2020 | Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer | BREAST CANCER RESEARCH AND TREATMENT |
| 1998 | Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients | BREAST CANCER RESEARCH AND TREATMENT |
| 1996 | Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression | BREAST CANCER RESEARCH AND TREATMENT |
| 1997 | Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression | BREAST CANCER RESEARCH AND TREATMENT |
